Clinical Research Directory
Browse clinical research sites, groups, and studies.
Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial
Sponsor: Xuekui Liu
Summary
This is a Phase III, randomized, open-label, multicenter clinical study for patients with locally advanced, resectable head and neck squamous cell carcinoma (HNSCC). The current standard treatment for this disease includes surgery or radiation, but many patients still experience tumor recurrence or metastasis. This study aims to evaluate whether adding an immunotherapy drug (Camrelizumab) to standard chemotherapy (nab-paclitaxel and cisplatin) before surgery or radiation can improve patient outcomes. Participants will be randomly assigned in a 1:1 ratio to one of two groups: Experimental Group: Receives 3 cycles of Camrelizumab combined with nab-paclitaxel and cisplatin as neoadjuvant (pre-operative) therapy. Control Group: Receives 3 cycles of nab-paclitaxel and cisplatin as neoadjuvant therapy. After 3 cycles of treatment, doctors will evaluate the tumors. Depending on the tumor response, its location, and the patient's preference, participants will then receive either surgery (radical resection) or radiation therapy combined with cisplatin. The main goal of this study is to compare the 2-year Event-Free Survival (EFS) between the two groups to see if the addition of Camrelizumab can prevent the disease from progressing or coming back. We will also monitor overall survival, organ preservation rates, and safety.
Official title: A Phase III, Open-Label, Multicenter, Randomized Clinical Trial of Neoadjuvant Camrelizumab Combined With Nab-Paclitaxel and Cisplatin in Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
212
Start Date
2027-01-01
Completion Date
2030-01-01
Last Updated
2026-11-19
Healthy Volunteers
No
Interventions
Camrelizumab
Humanized anti-PD-1 monoclonal antibody administered intravenously at 200 mg on Day 1 of each 21-day cycle for 3 cycles.
Nab-paclitaxel
Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
Cisplatin
Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.